Inovio Pharmaceuticals (INO) Non-Current Deferred Tax Liability (2010 - 2023)

Inovio Pharmaceuticals has reported Non-Current Deferred Tax Liability for 14 years, with the latest figure at $2.0 million in Q4 2023.

• Quarterly Non-Current Deferred Tax Liability rose 6119.18% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.0 million (up 6119.18% YoY) and the FY2023 annual result came in at $2.0 million, up 6119.18% from the prior year.
• Non-Current Deferred Tax Liability grew to $2.0 million in Q4 2023 per INO's latest filing, from $32046.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $2.0 million in Q4 2023 and troughed at $24766.0 in Q1 2019.
• A 5-year average of $129190.0 and a median of $32046.0 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2019 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2019, then jumped 6119.18% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $32046.0 in 2019, then changed by 0.0% to $32046.0 in 2020, then changed by 0.0% to $32046.0 in 2021, then changed by 0.0% to $32046.0 in 2022, then surged by 6119.18% to $2.0 million in 2023.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.0 million, $32046.0, and $32046.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.